AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: GlobeNewswire
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercializationACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome (DS) cohort; further interim results in Alzheimer’s disease (AD) and DS expected in 2025Enrollment progress in JNJ-2056 (ACI-35.030) ReTain Phase 2b trial in preclinical AD patients triggered second milestone payment of CHF 24.6 million; JNJ-2056 granted U.S. FDA Fast Track Designation in ADACI-7104.056 VacSYn Phase 2 trial demonstrated positive interim safety and immunogenicity results in Parkinson’s disease (PD); further interim results in H1 2025Cash resources of CHF 165.5 million at year end provides funding into Q1 2027, assuming no other milestones Lausanne, Switzerland, March 13, 2025 –
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD [Seeking Alpha]Seeking Alpha
- AC Immune posts positive data for Parkinson's immunotherapy [Yahoo! Finance]Yahoo! Finance
- AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s DiseaseGlobeNewswire
- AC Immune to Present at the Jefferies 2025 London Healthcare ConferenceGlobeNewswire
ACIU
Earnings
- 11/4/25 - Beat
ACIU
Sec Filings
- 12/11/25 - Form 6-K
- 11/4/25 - Form 6-K
- 10/3/25 - Form 144
- ACIU's page on the SEC website